Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn’s Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial

20260 citationsJournal Articlehybrid Open Access

Authors

ClinicalTrials. gov identifier, NCT03945019 (08 May 2019).

Good health and well-being

Published in: Advances in Therapy

Field-Weighted Citation Impact: 0.00